MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells
December 30th, 2025
This protocol provides a detailed approach to assessing m6A modification levels of specific RNA using MeRIP-qPCR.
My research focuses on osteosarcoma. I'm trying to address the advantages of MeRIP-qPCR compared with other technical and future research directions. To begin, remove the culture medium from a 3.5 centimeter dish containing osteosarcoma cells.
Gently wash once with pre-chilled PBS. Add an appropriate volume of RNA lysis buffer directly to the dish to fully lyse the cells. Gently pipette the suspension to homogenize.
Transfer the cell suspension into a 1.5 milliliter microcentrifuge tube. Then centrifuge the microcentrifuge tube at 1, 000 G for five minutes at four degrees Celsius. Carefully remove the microcentrifuge tube after centrifugation.
Using a one milliliter pipette, aspirate the supernatant completely without disturbing the pellet at the bottom. Then add 300 microliters of lysis buffer to the cell pellet. Mix thoroughly by inverting the tube 30 times until the solution appears clear and viscous with no visible clumps.
Then incubate the tube at room temperature for two minutes and proceed with RNA precipitation and purification. For methylated RNA immunoprecipitation, add the listed reagents to the tube. Close the cap of the PCR tube tightly for immuno capture.
Then place the PCR tube on a rotator or rolling shaker and incubate. Now transfer the PCR tube onto a magnetic stand. Allow the tube to sit for two minutes until the solution becomes clear and the beads are captured on the tube wall.
Then carefully aspirate and discard the supernatant without disturbing the beads. While keeping the tube on the magnetic stand, add 150 microliters of wash buffer. Remove the tube from the magnetic stand and tilt it upside down gently to fully resuspend the beads.
Return the tube to the magnetic stand. After two minutes when the solution clears, discard the supernatant. Now add 20 microliters of freshly prepared protein digestion working solution to the beads and incubate the PCR tube in a thermal cycler.
After incubation, place the tube back on the magnetic stand and carefully transfer the entire supernatant to a new 0.2 milliliter PCR tube. Add 20 microliters of RNA purification solution to each sample tube, negative control tube, and input tube. Then pipette 160 microliters of 100%ethanol.
Vortex the RNA binding beads to resuspend them. Then transfer two microliters of resuspended RNA binding beads to each tube. Place the tube on a magnetic stand, discard the supernatant and add 150 microliters of freshly prepared 90%ethanol.
After discarding the ethanol, pipette 13 microliters of elution buffer to the dried beads and incubate at room temperature for five minutes. Then carefully transfer the entire supernatant to a new RNAse-free PCR tube for further analysis, MeRIP-qPCR was used to assess N6-methyladenosine modification levels in the c-Myc RNA transcript in osteosarcoma cells. c-Myc enrichment using the anti-N6-methyladenosine antibody was significantly higher than with immunoglobulin G control in both hFOB1.19 and 143B cells.
The c-Myc N6-methyladenosine modification level was significantly higher in 143B cells than in hFOB1.19 cells. MeRIP-qPCR sensitively detects low abundance m6A enables regional localization and offers a low cost alternative to sequencing-based approaches with antibody enrichment efficiency. Future studies are expected to further integrate MeRIP-qPCR with nano-sequencing to improve accuracy, resolution, and the foundational interpretation of m6A modifications.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol provides a detailed approach to assessing m6A modification levels of specific RNA using MeRIP-qPCR. The study focuses on the application of this technique in osteosarcoma research, highlighting its advantages over other methods.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- RNA Modification
Background
- MeRIP-qPCR is a technique used to study m6A modifications in RNA.
- Osteosarcoma is a type of bone cancer that requires innovative research methods.
- Understanding RNA modifications can provide insights into cancer biology.
- Current methods for studying RNA modifications can be costly and complex.
Purpose of Study
- To assess m6A modification levels in RNA transcripts.
- To compare MeRIP-qPCR with other technical approaches.
- To explore future research directions integrating MeRIP-qPCR with nano-sequencing.
Methods Used
- Cell culture and lysis of osteosarcoma cells.
- RNA precipitation and purification techniques.
- Methylated RNA immunoprecipitation (MeRIP) followed by qPCR.
- Analysis of c-Myc RNA transcript for m6A modifications.
Main Results
- MeRIP-qPCR effectively detects m6A modifications in c-Myc RNA.
- c-Myc enrichment was significantly higher with anti-N6-methyladenosine antibody compared to control.
- Modification levels were higher in 143B cells than in hFOB1.19 cells.
- MeRIP-qPCR offers a low-cost alternative to sequencing-based methods.
Conclusions
- MeRIP-qPCR is a sensitive method for studying RNA modifications.
- Future studies should integrate MeRIP-qPCR with advanced sequencing techniques.
- This approach can enhance the understanding of m6A modifications in cancer research.
Frequently Asked Questions
Executive Industry Relevance
Quantitative detection of m6A RNA modifications using MeRIP-qPCR enables precise interrogation of epitranscriptomic regulation in disease-relevant systems such as osteosarcoma. This capability supports mechanistic de-risking and target validation at early discovery inflection points, informing portfolio decisions on RNA-modifying enzyme targets. The assay's reproducibility and specificity position it as a foundational tool for advancing RNA modification research in oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct measurement of m6A modification on candidate transcripts for functional target validation.
- Supports mechanistic de-risking by distinguishing methylation differences between cell models.
- Facilitates hypothesis-driven exploration of RNA regulatory networks in cancer biology.
- Provides quantitative evidence for prioritizing RNA-modifying enzymes as therapeutic targets.
Screening & Assay Development
- Delivers a validated workflow for antibody-based enrichment and qPCR quantification of RNA modifications.
- Ensures assay reproducibility and specificity through use of negative controls and standardized protocols.
- Enables scalable screening of m6A levels across multiple gene targets and cell lines.
- Supports downstream compound evaluation by establishing robust modification readouts.
Translational & Preclinical Research
- Aligns with disease-relevant models by quantifying m6A in osteosarcoma cell lines.
- Provides continuity from discovery to preclinical validation of epitranscriptomic biomarkers.
- Enables risk-adjusted advancement of RNA-targeted therapeutic hypotheses.
- Supports integration with advanced sequencing for higher-resolution translational studies.
Pipeline & Workflow Integration
The MeRIP-qPCR assay fits within the early discovery to preclinical continuum, enabling hypothesis testing, target validation, and biomarker quantification in disease-relevant systems.
- Discovery Biology: Supports null hypothesis testing of m6A modification effects on gene expression.
- Screening: Provides reproducible, quantitative outputs for comparing methylation across conditions.
- Analytics: Delivers antibody-enrichment efficiency and qPCR-based measurement for robust statistical analysis.
- Translational Research: Bridges discovery findings to preclinical models by quantifying modifications in relevant cell lines.
- Enterprise Reuse: Offers a standardized, scalable protocol adaptable to diverse RNA targets and disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in RNA modification biology and target validation.
- Operational Value: Enhances standardization, reproducibility, and cost-efficiency compared to sequencing-based methods.
- Strategic Value: Improves go/no-go decisions for RNA-targeted programs by providing robust mechanistic data.
- Portfolio Impact: Enables risk-adjusted prioritization of epitranscriptomic targets and pathways.
Implementation Considerations
- Requires expertise in RNA handling, immunoprecipitation, and qPCR analysis.
- Needs access to validated antibodies, magnetic bead systems, and quantitative PCR instrumentation.
- Demands rigorous cross-team standardization for reproducibility and data comparability.
- Adaptable to various cell models and gene targets with protocol optimization.
- Resolution and accuracy may be further enhanced by integrating with nano-sequencing platforms.
